Pmv Pharmaceuticals Inc (PMVP)

$1.32 -0.10 (-7.04%)
Market Cap 74.13M
Revenue (ttm) 0.00
Net Income (ttm) -77.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 623,162
Avg Vol 458,142
Day's Range N/A - N/A
Shares Out 53.33M
Stochastic %K 38%
Beta 1.41
Analysts Strong Sell
Price Target $4.75

Company Profile

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorpora...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 642 6670
Address:
400 Alexander Park Drive, Suite 301, Princeton, United States
GangsterX
GangsterX May. 12 at 6:12 PM
$TCRX $GERN $PMVP 3 biggies bet and still holding
1 · Reply
GangsterX
GangsterX May. 6 at 5:31 PM
$PMVP $GERN $REPL My 3 bigggesss... Looking good baby .... What did I say ??????
0 · Reply
GangsterX
GangsterX May. 6 at 3:07 PM
$PMVP I have big shix here.. This stock is slow shix... better move up...
0 · Reply
GangsterX
GangsterX May. 6 at 2:41 PM
$PMVP $GERN $REPL still holding 3 bigggies here
0 · Reply
chiefresident
chiefresident May. 3 at 5:58 PM
@Night_Owl_Biotech Have you researched $PMVP? very interesting company. early though.
1 · Reply
GangsterX
GangsterX May. 1 at 4:15 PM
$GERN $PMVP $REPL still holding all 3.. Biggies
0 · Reply
justiceforb_85
justiceforb_85 Apr. 29 at 8:41 PM
$PMVP added more. This should continue going up as we get more information from the FDA regarding a possible accelerated approval for rezatapopt in ovarian cancer TP53 Y220C mutation based on interval data.
0 · Reply
GangsterX
GangsterX Apr. 24 at 8:47 PM
$PMVP $GERN $REPL still holding.. 3 biggies
0 · Reply
DARKP00L
DARKP00L Apr. 22 at 12:05 PM
$PMVP 08:03 on Apr. 22 2026 PMV Pharmaceuticals Appoints Laurie Stelzer As Board Chair, Effective June 4, Succeeding Rich Heyman #tradeideas
0 · Reply
justiceforb_85
justiceforb_85 Apr. 16 at 2:14 AM
$PMVP don't understand why this continues to trade under cash.
1 · Reply
Latest News on PMVP
PMV Pharmaceuticals price target lowered to $5 from $6 at Oppenheimer

2026-05-13T11:57:40.000Z - 7 hours ago

PMV Pharmaceuticals price target lowered to $5 from $6 at Oppenheimer

PMV Pharmaceuticals reports Q1 EPS (34c), consensus (38c)

2026-05-12T16:19:03.000Z - 1 day ago

PMV Pharmaceuticals reports Q1 EPS (34c), consensus (38c)

PMV Pharmaceuticals chair Rich Heyman to depart, Laurie Stelzer to succeed

2026-04-22T12:35:31.000Z - 21 days ago

PMV Pharmaceuticals chair Rich Heyman to depart, Laurie Stelzer to succeed

KLRA

PMV Pharmaceuticals Announces Board Chair Transition

Apr 22, 2026, 8:00 AM EDT - 21 days ago

PMV Pharmaceuticals Announces Board Chair Transition

PMV Pharmaceuticals price target lowered to $4 from $16 at Evercore ISI

2026-04-13T13:54:36.000Z - 4 weeks ago

PMV Pharmaceuticals price target lowered to $4 from $16 at Evercore ISI

PMV Pharmaceuticals reports FY25 EPS ($1.48), consensus ($1.51)

2026-03-06T13:13:11.000Z - 2 months ago

PMV Pharmaceuticals reports FY25 EPS ($1.48), consensus ($1.51)

PMV Pharmaceuticals sees cash runway to end of 2Q27

2026-03-06T13:12:36.000Z - 2 months ago

PMV Pharmaceuticals sees cash runway to end of 2Q27

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

Mar 6, 2026, 8:00 AM EST - 2 months ago

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PMV Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 11:10 AM EST - 2 months ago

PMV Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

PMV Pharmaceuticals announces results of Phase 1 trial of rezatapopt in NEJM

2026-02-26T13:14:32.000Z - 2 months ago

PMV Pharmaceuticals announces results of Phase 1 trial of rezatapopt in NEJM

PMV Pharmaceuticals reports Q3 EPS (40c), consensus (40c)

2025-11-12T13:11:52.000Z - 6 months ago

PMV Pharmaceuticals reports Q3 EPS (40c), consensus (40c)

PMV Pharmaceuticals announces updated rezatapopt monotherapy interim data

2025-10-24T15:50:14.000Z - 7 months ago

PMV Pharmaceuticals announces updated rezatapopt monotherapy interim data

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

Oct 24, 2025, 11:39 AM EDT - 7 months ago

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 4:01 PM EDT - 7 months ago

PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

PMV Pharmaceuticals announces interim data from Phase 2 portion of PYNNACLE

2025-09-10T11:05:34.000Z - 8 months ago

PMV Pharmaceuticals announces interim data from Phase 2 portion of PYNNACLE

PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

Sep 10, 2025, 7:00 AM EDT - 8 months ago

PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

PMV Pharmaceuticals reports Q2 EPS (41c), consensus (38c)

2025-08-07T12:45:49.000Z - 9 months ago

PMV Pharmaceuticals reports Q2 EPS (41c), consensus (38c)

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

Aug 7, 2025, 8:42 AM EDT - 9 months ago

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

PMV Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 3:45 PM EDT - 1 year ago

PMV Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

PMV Pharmaceuticals Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 27, 2025, 11:30 AM EDT - 1 year ago

PMV Pharmaceuticals Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

May 23, 2025, 4:05 PM EDT - 1 year ago

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

PMV Pharmaceuticals reports Q1 EPS (34c), consensus (38c)

2025-05-09T12:12:55.000Z - 1 year ago

PMV Pharmaceuticals reports Q1 EPS (34c), consensus (38c)

PMV Pharmaceuticals sees cash runway to end of 2026

2025-05-09T12:12:28.000Z - 1 year ago

PMV Pharmaceuticals sees cash runway to end of 2026

PMV Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 3:10 PM EST - 1 year ago

PMV Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

PMV Pharmaceuticals sees cash runway to end of 2026

2025-03-03T13:11:53.000Z - 1 year ago

PMV Pharmaceuticals sees cash runway to end of 2026

PMV Pharmaceuticals reports FY24 EPS ($1.14), consensus ($1.02)

2025-03-03T13:05:19.000Z - 1 year ago

PMV Pharmaceuticals reports FY24 EPS ($1.14), consensus ($1.02)

PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights

Mar 3, 2025, 8:00 AM EST - 1 year ago

PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights

PMV Pharmaceuticals Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 12, 2025, 12:40 PM EST - 1 year ago

PMV Pharmaceuticals Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

PMV Pharmaceuticals files $200M mixed securities shelf

2024-11-20T13:05:16.000Z - 1 year ago

PMV Pharmaceuticals files $200M mixed securities shelf

PMV Pharmaceuticals upgraded at Oppenheimer ahead of rezatapopt readout

2024-11-08T11:30:21.000Z - 1 year ago

PMV Pharmaceuticals upgraded at Oppenheimer ahead of rezatapopt readout

PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer

2024-11-08T11:10:54.000Z - 1 year ago

PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer

PMV Pharmaceuticals reports Q3 EPS (37c), consensus (35c)

2024-11-07T13:09:40.000Z - 1 year ago

PMV Pharmaceuticals reports Q3 EPS (37c), consensus (35c)

PMV Pharmaceuticals sees cash runway to end of 2026

2024-11-07T13:09:19.000Z - 1 year ago

PMV Pharmaceuticals sees cash runway to end of 2026

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

May 29, 2024, 7:00 AM EDT - 2 years ago

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights

May 9, 2024, 8:00 AM EDT - 2 years ago

PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights

PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors

Mar 27, 2024, 8:00 AM EDT - 2 years ago

PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer

Mar 18, 2024, 4:01 PM EDT - 2 years ago

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer

PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights

Feb 29, 2024, 4:01 PM EST - 2 years ago

PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights

PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway

Jan 18, 2024, 4:01 PM EST - 2 years ago

PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway

PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development

Jan 5, 2024, 4:01 PM EST - 2 years ago

PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development

PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights

Nov 9, 2023, 8:00 AM EST - 2 years ago

PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights

PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation

Oct 12, 2023, 12:30 PM EDT - 2 years ago

PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar

Oct 11, 2023, 12:00 PM EDT - 2 years ago

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 20, 2023, 4:05 PM EDT - 2 years ago

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights

Aug 9, 2023, 8:00 AM EDT - 3 years ago

PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights

PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference

Jun 6, 2023, 4:01 PM EDT - 3 years ago

PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference

PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights

May 10, 2023, 8:00 AM EDT - 3 years ago

PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights

PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights

Mar 1, 2023, 8:00 AM EST - 3 years ago

PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March

Feb 28, 2023, 4:05 PM EST - 3 years ago

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March

PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

Nov 22, 2022, 8:00 AM EST - 3 years ago

PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

Nov 8, 2022, 8:00 AM EST - 3 years ago

PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors

Nov 4, 2022, 8:00 AM EDT - 3 years ago

PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors

PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights

Aug 9, 2022, 8:00 AM EDT - 4 years ago

PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights

PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

Jul 18, 2022, 8:00 AM EDT - 4 years ago

PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation

Jun 7, 2022, 12:00 PM EDT - 4 years ago

PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation

PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 26, 2022, 5:05 PM EDT - 4 years ago

PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights

May 10, 2022, 7:30 AM EDT - 4 years ago

PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights

PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 27, 2022, 10:30 AM EDT - 4 years ago

PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

Mar 1, 2022, 7:15 AM EST - 4 years ago

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

PMV Pharmaceuticals to Participate in the 42nd Annual Cowen Health Care Conference

Feb 28, 2022, 8:00 AM EST - 4 years ago

PMV Pharmaceuticals to Participate in the 42nd Annual Cowen Health Care Conference

PMV Pharmaceuticals to Participate in the Guggenheim Healthcare Talks 2022 Oncology Day

Feb 3, 2022, 8:00 AM EST - 4 years ago

PMV Pharmaceuticals to Participate in the Guggenheim Healthcare Talks 2022 Oncology Day

PMV Pharma Announces Changes to its Board of Directors

Jan 6, 2022, 8:00 AM EST - 4 years ago

PMV Pharma Announces Changes to its Board of Directors

PMV Pharma to Present at the Evercore ISI 4th Annual HealthCONx Conference

Nov 22, 2021, 8:00 AM EST - 4 years ago

PMV Pharma to Present at the Evercore ISI 4th Annual HealthCONx Conference

PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights

Nov 12, 2021, 7:15 AM EST - 4 years ago

PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights

PMV Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

Sep 2, 2021, 8:00 AM EDT - 5 years ago

PMV Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

PMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights

Aug 13, 2021, 8:00 AM EDT - 5 years ago

PMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights

PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference

Jun 9, 2021, 8:00 AM EDT - 5 years ago

PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference

PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights

May 14, 2021, 8:00 AM EDT - 5 years ago

PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights

PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference

May 5, 2021, 8:00 AM EDT - 5 years ago

PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference

PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021

Apr 10, 2021, 1:31 PM EDT - 5 years ago

PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021

PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum

Apr 6, 2021, 8:00 AM EDT - 5 years ago

PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum

PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021

Mar 10, 2021, 4:31 PM EST - 5 years ago

PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights

Mar 3, 2021, 4:01 PM EST - 5 years ago

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights

PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board

Feb 16, 2021, 8:00 AM EST - 5 years ago

PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board

PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference

Nov 24, 2020, 5:00 PM EST - 5 years ago

PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference

GangsterX
GangsterX May. 12 at 6:12 PM
$TCRX $GERN $PMVP 3 biggies bet and still holding
1 · Reply
GangsterX
GangsterX May. 6 at 5:31 PM
$PMVP $GERN $REPL My 3 bigggesss... Looking good baby .... What did I say ??????
0 · Reply
GangsterX
GangsterX May. 6 at 3:07 PM
$PMVP I have big shix here.. This stock is slow shix... better move up...
0 · Reply
GangsterX
GangsterX May. 6 at 2:41 PM
$PMVP $GERN $REPL still holding 3 bigggies here
0 · Reply
chiefresident
chiefresident May. 3 at 5:58 PM
@Night_Owl_Biotech Have you researched $PMVP? very interesting company. early though.
1 · Reply
GangsterX
GangsterX May. 1 at 4:15 PM
$GERN $PMVP $REPL still holding all 3.. Biggies
0 · Reply
justiceforb_85
justiceforb_85 Apr. 29 at 8:41 PM
$PMVP added more. This should continue going up as we get more information from the FDA regarding a possible accelerated approval for rezatapopt in ovarian cancer TP53 Y220C mutation based on interval data.
0 · Reply
GangsterX
GangsterX Apr. 24 at 8:47 PM
$PMVP $GERN $REPL still holding.. 3 biggies
0 · Reply
DARKP00L
DARKP00L Apr. 22 at 12:05 PM
$PMVP 08:03 on Apr. 22 2026 PMV Pharmaceuticals Appoints Laurie Stelzer As Board Chair, Effective June 4, Succeeding Rich Heyman #tradeideas
0 · Reply
justiceforb_85
justiceforb_85 Apr. 16 at 2:14 AM
$PMVP don't understand why this continues to trade under cash.
1 · Reply
GangsterX
GangsterX Apr. 14 at 4:30 PM
$PMVP This is just the beginning. You’ll see big shix in a couple of months. If I’m here, there’s nothing to worry about....only big $$$ in the bank. That’s why people on StockTwits always call me as “KungFu Trader.”
0 · Reply
GangsterX
GangsterX Apr. 14 at 4:14 PM
$GERN $PMVP $REPL still holding. They are all my biggies one
1 · Reply
GangsterX
GangsterX Apr. 13 at 6:40 PM
$GERN $PMVP they are my bigggies.. Never Sell
0 · Reply
GangsterX
GangsterX Apr. 9 at 8:05 PM
$PMVP $GERN $ALLO still holding all 3 but i sold ALLO half. pMVP will run up soon
0 · Reply
justiceforb_85
justiceforb_85 Mar. 13 at 5:12 PM
$PMVP holding steady.
0 · Reply
GangsterX
GangsterX Mar. 10 at 2:37 PM
$PMVP avg 1.17 and still holding.. Biggie here
0 · Reply
GangsterX
GangsterX Mar. 10 at 2:17 PM
$GERN $PMVP Hold for couple months. Stilll good
1 · Reply
GangsterX
GangsterX Mar. 9 at 7:02 PM
$GERN $PMVP holding biggies on those 2. pT 3
0 · Reply
Merlintrader
Merlintrader Mar. 7 at 8:47 PM
$PMVP https://www.merlintrader.com/pmv-pharmaceuticals-inc-pmvp/
0 · Reply
GangsterX
GangsterX Mar. 6 at 6:26 PM
$ALLO $GERN $PMVP these are 3 biggies bet.. focus on gern and pmvp.. sold half allo ... PT for gern and pmvp 3 bucks
1 · Reply
GangsterX
GangsterX Mar. 6 at 3:12 PM
$PMVP $GERN PT $3 ...
0 · Reply
GangsterX
GangsterX Mar. 6 at 2:52 PM
$ALLO $PMVP $GERN these are my biggies. I sold half allo. Still holding all 3. Right now, stock market is up and down base on Iran news and oil price. But i think everything will settle in 3-4 weeks. Just dón give up baby
0 · Reply